Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Clinical usefulness of bone turnover marker concentrations in osteoporosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Citrullination of fibrinogen by peptidylarginine deiminase 2 impairs fibrin clot structure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Reference values for leptin/adiponectin ratio in healthy children and adolescents

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical proteomics: Insights from IGF-I

    Research output: Contribution to journalReviewpeer-review

  4. Validation of image cytometry for sperm concentration measurement: Comparison with manual counting of 4010 human semen samples

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Bone phenotype of P2X4 receptor knockout mice: implication of a P2X7 receptor mutation?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Extracellular purines and bone homeostasis

    Research output: Contribution to journalReviewpeer-review

  • H A Morris
  • R Eastell
  • N R Jorgensen
  • E Cavalier
  • S Vasikaran
  • S A P Chubb
  • J A Kanis
  • C Cooper
  • K Makris
  • IFCC-IOF Working Group for Standardisation of Bone Marker Assays (WG-BMA)
View graph of relations

Current evidence continues to support the potential for bone turnover markers (BTM) to provide clinically useful information particularly for monitoring the efficacy of osteoporosis treatment. Many of the limitations identified earlier remain, principally in regard to the relationship between BTM and incident fractures. Important data are now available on reference interval values for CTX and PINP across a range of geographic regions and for individual clinical assays. An apparent lack of comparability between current clinical assays for CTX has become evident indicating the possible limitations of combining such data for meta-analyses. Harmonization of units for reporting serum/plasma CTX (ng/L) and PINP (μg/L) is recommended. The development of international collaborations continues with an important initiative to combine BTM results from clinical trials in osteoporosis in a meta-analysis and an assay harmonization program are likely to be beneficial. It is possible that knowledge derived from clinical studies can further enhance fracture risk estimation tools with inclusion of BTM together with other independent risk factors. Further data of the relationships between the clinical assays for CTX and PINP as well as physiological and pre-analytical factors contributing to variability in BTM concentrations are required.

Original languageEnglish
JournalClinica chimica acta; international journal of clinical chemistry
Volume467
Pages (from-to)34-41
Number of pages8
ISSN0009-8981
DOIs
Publication statusPublished - Apr 2017

    Research areas

  • Journal Article

ID: 52120881